Galena Biopharma Inc. is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. The company's lead program, NeuVax, is for the treatment of HER2 1+ and 2+ breast cancer patients in the adjuvant setting. The company has initiated its phase 3 trial under an approved special protocol assessment. Galena's second program, Folate Binding Protein-E39 (FBP), is a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial and breast cancers. A phase 1/2 trial has been initiated in ovarian and endometrial cancer.